SHPH Valuation

Shuttle Pharmaceuticals Holdings Inc

Add to Watchlist

Advanced Chart

3.600

-0.1(-2.703%)1D

Overview
Forecast
Valuation
Earnings

SHPH Relative Valuation

SHPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SHPH is overvalued; if below, it's undervalued.

Historical Valuation

Shuttle Pharmaceuticals Holdings Inc (SHPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Shuttle Pharmaceuticals Holdings Inc (SHPH) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.63

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Shuttle Pharmaceuticals Holdings Inc. (SHPH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.00

EV/EBIT

Shuttle Pharmaceuticals Holdings Inc. (SHPH) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.

0.00

Shuttle Pharmaceuticals Holdings Inc. (SHPH) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Shuttle Pharmaceuticals Holdings Inc. (SHPH) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Shuttle Pharmaceuticals Holdings Inc. (SHPH) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Shuttle Pharmaceuticals Holdings Inc (SHPH) has a current Price-to-Book (P/B) ratio of 0.28. Compared to its 3-year average P/B ratio of -0.33 , the current P/B ratio is approximately -184.75% higher. Relative to its 5-year average P/B ratio of -0.33, the current P/B ratio is about -184.75% higher. Shuttle Pharmaceuticals Holdings Inc (SHPH) has a Forward Free Cash Flow (FCF) yield of approximately -533.60%. Compared to its 3-year average FCF yield of -122.84%, the current FCF yield is approximately 334.40% lower. Relative to its 5-year average FCF yield of -122.84% , the current FCF yield is about 334.40% lower.

0.29

P/B

Median3y

-0.33

Median5y

-0.33

-514.49

FCF Yield

Median3y

-122.84

Median5y

-122.84

Competitors Valuation Multiple

The average P/S ratio for SHPH's competitors is 0.05, providing a benchmark for relative valuation. Shuttle Pharmaceuticals Holdings Inc Corp (SHPH) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SHPH.O

Shuttle Pharmaceuticals Holdings Inc

XORTX Therapeutics Inc

Theriva Biologics Inc

Loss

3.54M

GLMD.O

Galmed Pharmaceuticals Ltd

Loss

7.92M

Performance Decomposition

Market capitalization of SHPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SHPH in the past 1 year is driven by Unknown.